Patents by Inventor Hans Matter

Hans Matter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070173503
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.
    Type: Application
    Filed: August 31, 2006
    Publication date: July 26, 2007
    Applicant: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Gunter Muller, Cecile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
  • Publication number: 20070093482
    Abstract: The invention is directed to a compound of the formula I wherein the variables are as defined herein, or a stereoisomeric form thereof, mixture of stereoisomeric forms, in any ratio, or a salt thereof. Another aspect of the present invention is directed to a pharmaceutical composition comprising, a pharmaceutically effective amount of one or more compounds of formula I according to claim 1 in admixture with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 31, 2006
    Publication date: April 26, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Manfred SCHUDOK, Hans MATTER, Armin HOFMEISTER, Maxime LAMPILAS
  • Publication number: 20070088041
    Abstract: The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3?(glycogen synthase kinase-3?).
    Type: Application
    Filed: October 24, 2006
    Publication date: April 19, 2007
    Applicant: Sanofi-aventis Deutschland GmbH
    Inventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Guenter Mueller, Martin Bossart
  • Patent number: 7205315
    Abstract: The present invention is directed to a compound of formula (I), or a stereoisomer or a mixture of stereoisomer thereof in any ratio, or its physiologically tolerable salt, which is useful as an inhibitor of matrix metalloproteinase. The present invention is also directed to a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula (I); processes for their preparation; the use of a compound of formula (I) having activity as an matrix metalloproteinase inhibitor; and for the prophylaxis and therapy of disease states that involve an increase in the activity of matrix metalloproteinase.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: April 17, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Manfred Schudok, Hans Matter, Armin Hofmeister
  • Publication number: 20070072866
    Abstract: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase —3? (GSK-3?) which is believed to cause the neurodegeneration that results in these diseases.
    Type: Application
    Filed: August 28, 2006
    Publication date: March 29, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Karl SCHOENAFINGER, Swen HOELDER, David William WILL, Hans MATTER, Guenther MUELLER, Martin BOSSART
  • Publication number: 20070049573
    Abstract: The present invention relates to compounds of the formulae (I) and (Ia), wherein R0; R1; R3; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae (I) and (Ia) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae (I) and (Ia), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: August 25, 2006
    Publication date: March 1, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Armin BAUER, Michael WAGNER, Marc NAZARE, Volkmar WEHNER, Matthias URMANN, Hans MATTER
  • Patent number: 7153876
    Abstract: Compounds of formula I, in which R1, R2, A, and B having the definitions set forth in the claims, are valuable pharmacologically active compounds, which exhibit a strong antithrombotic effect and are suitable, for example, for treating thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. Also disclosed are processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: December 26, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
  • Publication number: 20060252752
    Abstract: The invention relates to a bicycloazaheterocyclyl carboxylic acid sulfonamide derivative of formula I herein, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use.
    Type: Application
    Filed: April 18, 2006
    Publication date: November 9, 2006
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Sven Ruf, Hans Matter, Volkmar Wehner, Reinhard Kirsch, Petra Lennig
  • Patent number: 7067665
    Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W-U-V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: June 27, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Nazare, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Patent number: 6953857
    Abstract: The present invention relates to compounds comprising the following formula: R0—Q—X—Q?—W—U—V—G—M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: October 11, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazaré, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Publication number: 20050165058
    Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W—U—V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
    Type: Application
    Filed: January 19, 2005
    Publication date: July 28, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazare, David Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
  • Publication number: 20050143419
    Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: July 7, 2004
    Publication date: June 30, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Anuschirwan Peyman, David Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
  • Patent number: 6906084
    Abstract: The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: June 14, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazaré, Melanie Essrich, David William Will, Hans Matter, Kurt Ritter, Volkmar Wehner
  • Publication number: 20050080127
    Abstract: The present invention is directed to a compound of formula (I), or a stereoisomer or a mixture of stereoisomer thereof in any ratio, or its physiologically tolerable salt, which is useful as an inhibitor of matrix metalloproteinase. The present invention is also directed to a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula (I); processes for their preparation; the use of a compound of formula (I) having activity as an matrix metalloproteinase inhibitor; and for the prophylaxis and therapy of disease states that involve an increase in the activity of matrix metalloproteinase.
    Type: Application
    Filed: September 27, 2004
    Publication date: April 14, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Hans Matter, Armin Hofmeister
  • Publication number: 20050043302
    Abstract: The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor Vila is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: August 26, 2004
    Publication date: February 24, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazare, Melanie Essrich, David Will, Hans Matter, Kurt Ritter, Volkmar Wehner
  • Publication number: 20050026918
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 3, 2005
    Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cecile Combeau, Ingrid Sassoon, Anke Steinmetz
  • Publication number: 20050009829
    Abstract: The present invention relates to compounds of the formula I, wherein R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazare, Michael Wagner, Volkmar Wehner, Hans Matter, Matthias Urmann, Kurt Ritter
  • Publication number: 20050009828
    Abstract: The present invention relates to compounds of the formula I wherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland
    Inventors: Marc Nazare, Volkmar Wehner, David Will, Kurt Ritter, Matthias Urmann, Hans Matter
  • Publication number: 20050004166
    Abstract: The invention relates to a bicycloazaheterocyclyl carboxylic acid sulfonamide derivative of formula I herein, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use.
    Type: Application
    Filed: January 5, 2004
    Publication date: January 6, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Sven Ruf, Hans Matter, Volkmar Wehner, Reinhard Kirsch, Petra Stahl
  • Publication number: 20040235824
    Abstract: The present invention relates to a compound of the formula I 1
    Type: Application
    Filed: May 19, 2004
    Publication date: November 25, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazare, Volkmar Wehner, Volker Laux, Matthias Urmann, Armin Bauer, Hans Matter